These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9041318)

  • 61. MUCOVISCIDOSIS ILEUS.
    HALLBERG D
    Acta Chir Scand; 1964 Aug; 128():201-9. PubMed ID: 14196500
    [No Abstract]   [Full Text] [Related]  

  • 62. Pricing of drugs with heterogeneous health insurance coverage.
    Ferrara I; Missios P
    J Health Econ; 2012 Mar; 31(2):440-56. PubMed ID: 22484368
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recently introduced generics helped PBM control its costs.
    Manag Care; 2005 Nov; 14(11):77. PubMed ID: 16350653
    [No Abstract]   [Full Text] [Related]  

  • 64. 25th annual prescription survey: Albany College of Pharmacy of Union University.
    DeNuzzo RV
    Med Mark Media; 1981 Apr; 16(4):31-2, 34-51. PubMed ID: 10250762
    [No Abstract]   [Full Text] [Related]  

  • 65. Intestinal obstruction as a late complication of fibrocystic disease of the pancreas (mucosis).
    FISHER OD
    Arch Dis Child; 1954 Jun; 29(145):262-4. PubMed ID: 13159373
    [No Abstract]   [Full Text] [Related]  

  • 66. Capitation for pharmacy services: rationale, findings, and future plans.
    Lipson DP; Yesalis CE; Norwood GJ
    Med Mark Media; 1980 Oct; 15(10):25-32. PubMed ID: 10249119
    [No Abstract]   [Full Text] [Related]  

  • 67. [Prescription of generic drugs to privately insured persons].
    Wild F
    Versicherungsmedizin; 2012 Dec; 64(4):190-2. PubMed ID: 23236709
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Could a Wal-Mart PBM succeed?
    Carroll J
    Manag Care; 2008 Apr; 17(4):36-8. PubMed ID: 18464572
    [No Abstract]   [Full Text] [Related]  

  • 69. Generic and alternative brand-name pharmaceutical equivalents: select with caution.
    Hendeles L; Hochhaus G; Kazerounian S
    Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793
    [No Abstract]   [Full Text] [Related]  

  • 70. [Can we transfer the mechanisms of the generics market to biosimilars?].
    Jacke CO; Wild F
    Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potential impact of prepayment on Medicaid drug costs.
    Yesalls CE; Norwood GJ; Lipson DP
    Contemp Pharm Pract; 1979; 2(2):87-94. PubMed ID: 10297462
    [No Abstract]   [Full Text] [Related]  

  • 72. Prescription-drug coupons--no such thing as a free lunch.
    Ross JS; Kesselheim AS
    N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672
    [No Abstract]   [Full Text] [Related]  

  • 73. Potent statin goes generic.
    Johns Hopkins Med Lett Health After 50; 2006 Dec; 18(10):7. PubMed ID: 17290530
    [No Abstract]   [Full Text] [Related]  

  • 74. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
    Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
    J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
    [No Abstract]   [Full Text] [Related]  

  • 75. Treating and Preventing HIV with Generic Drugs - Barriers in the United States.
    Martin EG; Schackman BR
    N Engl J Med; 2018 Jan; 378(4):316-319. PubMed ID: 29365306
    [No Abstract]   [Full Text] [Related]  

  • 76. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes.
    Swinburn B; Milne RJ; Richards M; Begg E; Foote S; Jackson R
    N Z Med J; 2000 Oct; 113(1119):425-8. PubMed ID: 11127362
    [No Abstract]   [Full Text] [Related]  

  • 78. An asfaliogenic complication arising from profit-motivated decision-making.
    Irish MS; Glick PL; Borowitz DS; Kantos M
    Pediatrics; 1997 Mar; 99(3):503-4. PubMed ID: 9041318
    [No Abstract]   [Full Text] [Related]  

  • 79. Progressive pan-colonic fibrosis secondary to oral administration of pancreatic enzymes.
    Moss RL; Musemeche CA; Feddersen RM
    Pediatr Surg Int; 1998 Mar; 13(2-3):168-70. PubMed ID: 9563037
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis.
    Taylor CJ; Dodge JA
    Lancet; 1994 Jan; 343(8889):110. PubMed ID: 7903735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.